GO:0030977 taurine binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0030977 (taurine binding) is a molecular function defined as the binding of taurine (2-aminoethanesulfonic acid) to a protein or macromolecule [1,4].
• Taurine binding proteins include the taurine transporter (SLC6A6/TauT), taurine/alpha-ketoglutarate dioxygenase (TauD), and the insulin receptor, where taurine may act as a modulator [2,4,8].
• Taurine binding can allosterically modulate receptor function, as shown for flunitrazepam binding to synaptic membranes.
• Taurine binding is implicated in diverse physiological processes including retinal function, ferroptosis inhibition, and neuroprotection [1,3,6].
• Dysregulation of taurine binding proteins is linked to prostate cancer, Alzheimer's disease, and intervertebral disc degeneration [1,5,6].
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal dissection of taurine binding proteins in disease [1,4,8].
Description
Taurine (2-aminoethanesulfonic acid) is one of the most abundant free amino acids in mammals and participates in numerous physiological processes, including osmoregulation, bile acid conjugation, retinal development, and neuroprotection. The molecular function GO:0030977, taurine binding, describes the selective interaction of taurine with proteins or macromolecules. This function is central to taurine transport, metabolism, and signaling, as it underlies the first step in taurine recognition by its molecular partners [4,8]. Understanding taurine binding is therefore critical for deciphering how taurine exerts its cellular effects. Recent structural and biochemical studies have begun to reveal the atomic details of taurine binding sites in transporters and enzymes, providing a foundation for therapeutic targeting [4,8]. Moreover, taurine binding to non-canonical targets such as the insulin receptor suggests broader regulatory roles beyond classical transport and metabolism. In disease contexts, taurine binding proteins have been implicated in cancer, neurodegeneration, and inflammatory conditions, making GO:0030977 a focal point for both basic and translational research [1,5,6].
taurine binding At A Glance
| GO ID | GO:0030977 |
|---|---|
| GO term | taurine binding |
| Ontology | molecular_function |
| Synonym | none |
| Definition | Binding to taurine. |
| Major function | Selective non-covalent interaction with taurine, enabling transport, metabolism, or modulation of protein activity. |
| Example proteins | SLC6A6 (taurine transporter), TauD (taurine dioxygenase), insulin receptor [2,4,8] |
| Related diseases | Prostate cancer, Alzheimer's disease, intervertebral disc degeneration [1,5,6] |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, structural biology, binding assays [1,4,8] |
What Is GO:0030977?
According to the Gene Ontology, GO:0030977 (taurine binding) is defined as the binding to taurine. In other words, it is the molecular function of selectively and non-covalently interacting with taurine, a sulfonic acid analog of beta-alanine. This term is used to annotate gene products that physically bind taurine, such as transporters, enzymes, and receptors, and it does not imply any downstream catalytic or signaling activity by itself [1,4].
Why Is taurine binding Important in Cell Biology?
Taurine binding is a fundamental molecular event that governs taurine homeostasis and signaling. It is essential for the function of the taurine transporter, which maintains intracellular taurine levels required for cell volume regulation and antioxidant defense. In enzymes such as taurine/alpha-ketoglutarate dioxygenase, taurine binding initiates its catabolism, influencing sulfur metabolism. Beyond these classical roles, taurine binding to the insulin receptor may modulate insulin signaling, linking taurine to metabolic regulation. In the retina, taurine binding proteins are critical for visual function, and taurine deficiency leads to retinal degeneration. Recent studies show that taurine binding to cellular targets can inhibit ferroptosis in prostate cancer and suppress amyloid-beta aggregation in Alzheimer's disease models, highlighting its therapeutic potential [1,6]. Thus, understanding taurine binding at the molecular level is vital for developing interventions in cancer, neurodegeneration, and metabolic disorders.
• Taurine binding to the taurine transporter (SLC6A6) is required for taurine uptake, which protects cells from osmotic stress and oxidative damage.
• Taurine binding to taurine/alpha-ketoglutarate dioxygenase (TauD) is the first step in taurine degradation, affecting sulfur and energy metabolism.
• Taurine binding to the insulin receptor may allosterically modulate insulin signaling, suggesting a role in glucose homeostasis.
• Taurine binding to synaptic membranes modulates flunitrazepam binding, indicating an interaction with GABA-A receptor function.
• In the retina, taurine binding proteins are essential for photoreceptor survival; taurine deficiency causes retinal degeneration.
• Taurine binding inhibits ferroptosis in prostate cancer by mediating crosstalk between tumor cells and macrophages.
• Taurine binding suppresses amyloid-beta aggregation and attenuates Alzheimer's disease pathologies in mouse models and cerebral organoids.
• Taurine binding enhances mitophagy and restricts MtdsRNA-mediated pyroptosis in nucleus pulposus cells, linking it to intervertebral disc degeneration.
• CRISPR-based editing of genes encoding taurine-binding proteins enables causal studies of their roles in disease [1,4,8].
• Targeting taurine binding sites with small molecules or biologics may offer new therapeutic strategies for cancer and neurodegeneration [1,6].
Molecular Mechanism of taurine binding
Substrate recognition and binding pocket
In simple terms: Taurine fits into a specific pocket in a protein, like a key in a lock.
Taurine binding typically occurs in a substrate-binding pocket lined with polar and charged residues that recognize the sulfonate group and the amino group of taurine. In the human taurine transporter, structural studies have revealed a central binding site where taurine is coordinated by aromatic and polar residues, and electrostatic perturbations in this pocket determine substrate selectivity [4,8]. For taurine/alpha-ketoglutarate dioxygenase, the binding pocket includes a facial triad of iron-coordinating residues that position taurine for oxidative attack.
Conformational changes upon binding
In simple terms: When taurine binds, the protein changes shape to perform its function.
Binding of taurine often induces conformational changes in the protein. In the taurine transporter, substrate binding triggers closure of the extracellular gate, facilitating transport across the membrane. In the insulin receptor, molecular docking studies suggest that taurine binds to specific sites and may induce allosteric changes that modulate receptor activity. Similarly, taurine binding to synaptic membranes allosterically modulates flunitrazepam binding, likely by altering the conformation of the GABA-A receptor complex.
Cofactor requirements and catalysis
In simple terms: Some taurine-binding enzymes need extra helpers, like iron, to work.
For enzymes that bind taurine, cofactors are often required. Taurine/alpha-ketoglutarate dioxygenase is a non-heme iron enzyme that uses alpha-ketoglutarate and molecular oxygen to hydroxylate taurine, with the iron center coordinated by the binding pocket. This cofactor dependency distinguishes taurine binding for catalysis from taurine binding for transport or modulation, which typically does not require metal ions [4,8].
Regulation of taurine binding
In simple terms: Cells can adjust how much taurine binds by changing the number or activity of binding proteins.
Taurine binding is regulated at multiple levels. The expression of taurine-binding proteins such as the taurine transporter is controlled by osmotic stress and hormones, affecting the availability of binding sites. Post-translational modifications, such as phosphorylation, can modulate the affinity or trafficking of these proteins. Additionally, the local concentration of taurine, which is influenced by diet and synthesis, directly affects the extent of binding. In disease states, altered expression of taurine-binding proteins has been observed, suggesting dysregulation of this function [1,5,6].
Key Genes Involved in GO:0030977 taurine binding
The following genes encode proteins that bind taurine or are directly involved in taurine binding-related processes, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC6A6 | Taurine transporter; mediates sodium- and chloride-dependent taurine uptake | Structural studies reveal binding pocket; knockout models show taurine depletion effects |
| TauD | Taurine/alpha-ketoglutarate dioxygenase; catalyzes taurine degradation | Model enzyme for taurine binding and iron-dependent catalysis |
| INSR | Insulin receptor; potential taurine binding site modulates signaling | Docking studies suggest allosteric regulation by taurine |
| GABRA1 | GABA-A receptor subunit; taurine modulates flunitrazepam binding | Taurine binding allosterically affects benzodiazepine site |
| GABRB2 | GABA-A receptor subunit; may contribute to taurine modulation | Potential target for taurine binding studies |
| GABRG2 | GABA-A receptor subunit; involved in synaptic inhibition | Taurine binding may influence receptor function |
| SLC6A8 | Creatine transporter; related to taurine transport family | Comparative studies of binding pockets |
| SLC6A1 | GABA transporter; shares structural homology with taurine transporter | Model for understanding taurine binding selectivity |
| SLC6A2 | Norepinephrine transporter; family member | Structural comparisons for binding site analysis |
| SLC6A3 | Dopamine transporter; family member | Insights into substrate recognition |
| SLC6A4 | Serotonin transporter; family member | Homology modeling of taurine binding |
| SLC6A5 | Glycine transporter; family member | Comparative binding studies |
| SLC6A7 | Proline transporter; family member | Evolutionary context of taurine binding |
| SLC6A9 | Glycine transporter 1; family member | Structural basis for substrate specificity |
| SLC6A11 | GABA transporter 3; family member | Related transport mechanisms |
| SLC6A12 | Betaine/GABA transporter; binds taurine with low affinity | Substrate promiscuity studies |
| SLC6A13 | GABA transporter 2; family member | Comparative analysis |
| SLC6A14 | Amino acid transporter; may transport taurine | Broad substrate specificity |
How Is taurine binding Regulated?
Taurine binding is regulated by the availability of taurine, which depends on dietary intake and endogenous synthesis, as well as by the expression levels and post-translational modifications of taurine-binding proteins [3,4]. Osmotic stress and hormones can alter the expression of the taurine transporter, thereby modulating taurine binding capacity. In addition, allosteric interactions with other ligands, such as benzodiazepines, can influence taurine binding to synaptic membranes. In disease states, inflammatory cytokines and oxidative stress may affect the function of taurine-binding proteins, as seen in prostate cancer and intervertebral disc degeneration [1,5].
taurine binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC6A6 | Taurine transporter deficiency; retinal degeneration, osmotic stress | Knockout mice, patient-derived organoids |
| TauD | Taurine catabolism defects; sulfur metabolism disorders | Bacterial knockout, enzymatic assays |
| INSR | Insulin resistance, diabetes | Point mutation knock-in mice, cell lines |
| GABRA1 | Epilepsy, anxiety; taurine modulation of GABA-A receptor | Knock-in mice with mutated binding site |
| APP | Alzheimer's disease; taurine suppresses amyloid-beta aggregation | 5XFAD mice, cerebral organoids |
Taurine binding in prostate cancer
Taurine binding plays a role in prostate cancer by inhibiting ferroptosis through crosstalk between tumor cells and tumor-associated macrophages. Xiao et al. (2024) demonstrated that taurine inhibits ferroptosis in prostate cancer cells, and this effect is mediated by the interaction between tumor cells and macrophages. The study suggests that taurine binding to yet-unidentified targets in the tumor microenvironment contributes to ferroptosis resistance, highlighting a potential therapeutic avenue.
Taurine binding in Alzheimer's disease
In Alzheimer's disease, taurine binding suppresses amyloid-beta aggregation and attenuates pathologies. Lee et al. (2025) showed that taurine treatment reduces amyloid-beta aggregation and improves cognitive deficits in 5XFAD mice and patient-derived cerebral organoids. The binding of taurine to amyloid-beta or associated proteins may interfere with aggregation, although the exact binding partners remain to be fully characterized.
Taurine binding in intervertebral disc degeneration
Taurine binding enhances mitophagy and restricts MtdsRNA-mediated pyroptosis in nucleus pulposus cells, as reported by Ou et al. (2025). This study links taurine binding to the regulation of cell death pathways in intervertebral disc degeneration, suggesting that taurine supplementation or targeting its binding proteins could mitigate disc degeneration.
Taurine binding in retinal function
Taurine binding is essential for retinal function. Lombardini (1991) reviewed evidence that taurine deficiency leads to retinal degeneration, and taurine binding proteins in the retina are critical for photoreceptor survival. The specific binding partners and their roles in retinal physiology continue to be investigated.
From taurine binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of taurine transporter affect taurine binding and cellular taurine levels? | SLC6A6 knockout cell line (e.g., HEK293) |
| Does a point mutation in the taurine binding pocket alter substrate selectivity? | Point mutation knock-in in SLC6A6 or TauD [4,8] |
| Can taurine binding to the insulin receptor modulate insulin signaling? | INSR point mutation knock-in cells |
| Does overexpression of taurine-binding protein enhance ferroptosis resistance? | Overexpression of SLC6A6 in prostate cancer cells |
| Can tagged taurine-binding protein be used to map binding sites? | Knock-in of epitope-tagged SLC6A6 |
| Does taurine binding to GABA-A receptor modulate benzodiazepine effects? | Knock-in mice with mutated GABA-A receptor subunits |
How to Study the taurine binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Cryo-EM | 3D structure of protein-taurine complex | Determine binding pocket of SLC6A6 |
| Isothermal titration calorimetry | Binding affinity (Kd) and stoichiometry | Quantify taurine binding to TauD |
| Molecular docking | Predicted binding poses and scores | Identify taurine binding sites on INSR |
| CRISPR knockout screen | Genes essential for taurine-mediated phenotypes | Discover ferroptosis regulators |
| Western blot | Protein expression levels | Validate knockout or overexpression [1,4] |
| Fluorescence microscopy | Subcellular localization of taurine-binding proteins | Assess trafficking of SLC6A6 |
| Amyloid-beta aggregation assay | Aggregation kinetics | Test taurine binding effect in Alzheimer's models |
| Mitophagy flux assay | Autophagic degradation of mitochondria | Evaluate taurine binding in disc degeneration |
Structural biology and binding assays
X-ray crystallography and cryo-electron microscopy have been used to determine the structure of the taurine transporter bound to taurine, revealing the binding pocket and conformational changes. Isothermal titration calorimetry and surface plasmon resonance can measure binding affinity and kinetics of taurine to purified proteins. These methods provide direct evidence for GO:0030977.
Molecular docking and simulation
Molecular docking studies have predicted potential taurine binding sites on the insulin receptor, offering hypotheses for experimental validation. Molecular dynamics simulations can explore the stability of taurine binding and induced conformational changes.
CRISPR-based genetic screens
Genome-wide CRISPR knockout screens can identify genes required for taurine binding or taurine-mediated phenotypes, such as ferroptosis resistance. Such screens link taurine binding to specific cellular pathways and disease models.
Functional assays in disease models
In vitro assays measuring ferroptosis, amyloid-beta aggregation, or mitophagy can assess the functional consequences of taurine binding [1,5,6]. These assays are often combined with CRISPR editing to establish causality.
How CRISPR Can Be Used to Study GO:0030977 taurine binding
Knockout
CRISPR knockout of genes encoding taurine-binding proteins, such as SLC6A6 or TauD, allows researchers to study the loss-of-function consequences on taurine binding and downstream phenotypes. For example, SLC6A6 knockout cells show reduced taurine uptake and increased susceptibility to oxidative stress. Knockout of TauD in bacteria abolishes taurine degradation.
Point Mutation
Point mutations in the taurine binding pocket can be introduced using CRISPR base editing or homology-directed repair to dissect the contribution of specific residues to taurine binding affinity and selectivity. Such mutations in SLC6A6 or TauD have been used to alter electrostatic interactions and substrate specificity [4,8].
Knock-in
Knock-in of epitope tags or reporter genes into endogenous loci of taurine-binding proteins enables visualization and purification of the protein in its native context. This approach has been used to study the trafficking and localization of the taurine transporter. Knock-in of disease-associated mutations can model human disorders linked to taurine binding.
Overexpression
Overexpression of taurine-binding proteins, such as SLC6A6, can enhance taurine binding capacity and protect cells from ferroptosis or other stresses. This strategy is useful for gain-of-function studies and for producing recombinant protein for structural analysis [1,4].
How EDITGENE Supports taurine binding Research
Researchers studying taurine binding-related genes often need to determine whether a candidate gene is causally involved in taurine binding and its downstream biology. EDITGENE provides a comprehensive suite of CRISPR services to enable such investigations, from gene knockout to precise point mutations and knock-in models.
Contact EDITGENE today to design your custom CRISPR model for taurine binding research.
Frequently Asked Questions About taurine binding
What is taurine binding?
Taurine binding is the molecular function defined by GO:0030977, which describes the selective, non-covalent interaction of taurine with a protein or macromolecule [1,4].
What genes are involved in taurine binding?
Genes encoding taurine-binding proteins include SLC6A6 (taurine transporter), TauD (taurine dioxygenase), and INSR (insulin receptor), among others [2,4,8].
What is the GO ID for taurine binding?
The Gene Ontology ID for taurine binding is GO:0030977.
Which diseases are linked to taurine binding?
Taurine binding has been implicated in prostate cancer, Alzheimer's disease, intervertebral disc degeneration, and retinal degeneration [1,3,5,6].
How does taurine bind to the taurine transporter?
Taurine binds to a central pocket in SLC6A6, coordinated by polar and aromatic residues, triggering conformational changes for transport.
Can taurine bind to the insulin receptor?
Molecular docking studies suggest potential taurine binding sites on the insulin receptor, which may modulate its activity.
What methods are used to study taurine binding?
Methods include cryo-EM, isothermal titration calorimetry, molecular docking, and CRISPR-based genetic screens [1,2,4,8].
How does taurine binding affect ferroptosis?
Taurine binding inhibits ferroptosis in prostate cancer by mediating crosstalk between tumor cells and macrophages.
Is taurine binding involved in Alzheimer's disease?
Yes, taurine binding suppresses amyloid-beta aggregation and attenuates Alzheimer's disease pathologies in mouse models and cerebral organoids.
What CRISPR models are available for taurine binding research?
EDITGENE offers knockout, point mutation, knock-in, and overexpression models for genes encoding taurine-binding proteins, as well as CRISPR library screening [1,4,8].
Conclusion
Taurine binding (GO:0030977) is a fundamental molecular function with broad implications for physiology and disease. From its role in taurine transport and metabolism to its emerging functions in cancer, neurodegeneration, and disc degeneration, taurine binding represents a fertile area for research. Advances in structural biology and CRISPR-based editing are providing unprecedented insights into the mechanisms and therapeutic potential of taurine-binding proteins. Continued investigation of this function will likely yield new strategies for treating taurine-related disorders.
References
- 1. Xiao H et al.. 2024. Taurine Inhibits Ferroptosis Mediated by the Crosstalk between Tumor Cells and Tumor-Associated Macrophages in Prostate Cancer.. Adv Sci (Weinh) 11(3):e2303894 PMID: 38031260
- 2. da Silva Junior JA et al.. 2022. Potential Binding Sites for Taurine on the Insulin Receptor: A Molecular Docking Study.. Adv Exp Med Biol 1370:257-266 PMID: 35882801
- 3. Lombardini JB. 1991. Taurine: retinal function.. Brain Res Brain Res Rev 16(2):151-69 PMID: 1760655
- 4. Qi Y et al.. 2026. Structural mechanism of substrate binding and inhibition of human taurine transporter.. Nat Commun 17(1) PMID: 41857056
- 5. Ou Z et al.. 2025. Taurine can restrict MtdsRNA mediated pyroptosis by enhancing mitophagy in nucleus pulposus cells.. Cell Commun Signal 23(1):423 PMID: 41068939
- 6. Lee H et al.. 2025. Taurine suppresses Aβ aggregation and attenuates Alzheimer's disease pathologies in 5XFAD mice and patient-derived cerebral organoids.. Biomed Pharmacother 191:118527 PMID: 40913913
- 7. Quinn MR et al.. 1992. Taurine allosterically modulates flunitrazepam binding to synaptic membranes.. J Neurosci Res 33(1):136-41 PMID: 1453477
- 8. Ali HS et al.. 2022. Electrostatic Perturbations in the Substrate-Binding Pocket of Taurine/α-Ketoglutarate Dioxygenase Determine its Selectivity.. Chemistry 28(9):e202104167 PMID: 34967481
